HYPERA S.A. ("Company"), as response to the news published in the local press "O Estado de S. Paulo" on the date hereof, informs that:
1. The interlocutory injunction (ação cautelar) related to the searches and seizures, as released to the market in the Material Fact of April 10, 2018, is being heard in private.
2. The interlocutory injunction is based on the plea bargain agreement executed by the former executive Mr. Nelson Mello, and on information internally verified by the company and provided
to the authorities in 2016.
3. The searches and seizures were also carried out in the residences of Messrs. João Alves de Queiroz Filho, Claudio Bergamo dos Santos, and two employees with administrative positions.
4. The Company reiterates that, after becoming aware of the facts disclosed by the referred former executive on 2016, is taking all the appropriate measures and will continue to collaborate with the investigation.
São Paulo, April 20, 2018
HYPERA S.A.
Breno Toledo Pires de Oliveira
Chief Financial Officer (CFO) and Investor Relations Executive Officer .
Attachments
Original document
Permalink
Disclaimer
Hypera SA published this content on 20 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 April 2018 12:21:04 UTC
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
HYPERA S.A. 
